
COVID-19 Monoclonal Antibodies: FDA Authorized Bebtelovimab
COVID-19 Monoclonal Antibodies: FDA Authorized Bebtelovimab On February 11, the FDA authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply: They have a positive COVID-19 test result They’re at high-risk for progression to severe COVID-19 Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them CMS created



